Morisaka Hiroyuki, Imaizumi Akira, Wumu Tihan, Ii Takanori, Araki Takuji, Onishi Hiroshi
Department of Radiology, University of Yamanashi, Chuo, Yamanashi.
Department of Radiology, Sizuoka General Hospital, Aoiku, Sizuoka, Japan.
J Comput Assist Tomogr. 2025;49(5):745-750. doi: 10.1097/RCT.0000000000001727. Epub 2025 Jan 27.
This study aims to identify factors associated with the detectability of the right adrenal vein (RAV) on preoperative contrast-enhanced CT scans of adrenal venous sampling (AVS) in the era of high-resolution CT (HRCT).
In this retrospective study, 36 patients (15 men and 21 women; mean age, 56 y) who underwent preoperative contrast-enhanced CT [11 patients in HRCT with 0.25 mm detector matrix (Cannon Medical Systems) and 25 patients in conventional multidetector CT with 0.5 mm matrix] were included. A contrast agent dose of 600 mgI/kg was injected, and CT images were acquired at a fixed scan delay of 50 and 80 seconds. Adrenal venography and venous sampling were performed for the diagnosis of suspected primary hyperaldosteronism. The qualitative detectability of RAV on preoperative CT was assessed with adrenal venography as a reference. Clinical and imaging factors associated with a good detectability of RAV were analyzed via regression analysis. Optimal acquisition timing was assessed by analyzing the time-intensity curve and contrast enhancement pattern of the inferior vena cava using CT data from a separate cohort (n=5).
The qualitative detectability of RAV was deemed good in 15 patients and poor in 21 patients. Regression analysis revealed that only heterogeneous enhancement of inferior vena cava with bolus high attenuation, corresponding to an optimal acquisition timing from time-intensity curve analysis, was associated with a good detectability of RAV (odds ratio, 5.06). The use of HRCT was not statistically significant.
Optimal acquisition timing is a crucial factor for the detectability of RAV in preprocedural CT for AVS, while high-resolution 0.25 detector CT appears to have limited significance.
本研究旨在确定在高分辨率CT(HRCT)时代,肾上腺静脉采样(AVS)术前对比增强CT扫描中与右肾上腺静脉(RAV)可检测性相关的因素。
在这项回顾性研究中,纳入了36例患者(15例男性和21例女性;平均年龄56岁),这些患者均接受了术前对比增强CT检查[11例使用0.25mm探测器矩阵的HRCT(佳能医疗系统公司),25例使用0.5mm矩阵的传统多排探测器CT]。注射600mgI/kg的造影剂,并在固定的扫描延迟时间50秒和80秒时采集CT图像。进行肾上腺静脉造影和静脉采样以诊断疑似原发性醛固酮增多症。以肾上腺静脉造影为参考,评估术前CT上RAV的定性可检测性。通过回归分析分析与RAV良好可检测性相关的临床和影像因素。通过分析来自另一个队列(n=5)的CT数据的时间-强度曲线和下腔静脉的对比增强模式,评估最佳采集时间。
15例患者的RAV定性可检测性被认为良好,21例患者的RAV定性可检测性较差。回归分析显示,只有下腔静脉团注高衰减时的不均匀强化(对应于时间-强度曲线分析得出的最佳采集时间)与RAV的良好可检测性相关(优势比,5.06)。HRCT的使用无统计学意义。
最佳采集时间是AVS术前CT中RAV可检测性的关键因素,而0.25探测器的高分辨率CT似乎意义有限。